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Abstract
In a randomized study of pemetrexed plus cisplatin followed by maintenance geﬁtinib (PC/G) or geﬁtinib
monotherapy (G) in East Asian never-smoker patients with advanced nonsquamous nonesmall-cell lung
cancer, the quality of life symptoms were more favorable in the G group than in the PC/G group. In patients with
wild-type epidermal growth factor receptor, tumor-related symptoms appeared to improve more with PC/G
than with G.
Background: The efﬁcacy results from an open-label, randomized, multicenter study found no signiﬁcant difference in
progression-free survival between pemetrexed plus cisplatin followed by maintenance geﬁtinib (PC/G) and geﬁtinib
monotherapy (G) in patients with advanced nonsquamous nonesmall-cell lung cancer (NSCLC) and unknown
epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). The present report describes the
quality of life (QoL) results from that trial. Patients and Methods: Chemotherapy-naive, East Asian, light ex-smokers
or never-smokers with advanced nonsquamous NSCLC and unknown EGFR mutation status (n ¼ 236) were randomly
assigned (1:1) to PC/G or G. EGFR mutation status was subsequently determined for 74 patients. The symptoms and
QoL were assessed using the Lung Cancer Symptom Scale (LCSS). The time to worsening of symptoms (TWS) was
analyzed using the Kaplan-Meier method. Results: In the overall population, the TWS was generally longer in the G
group (n ¼ 109) than in the PC/G group (n ¼ 109) for the LCSS symptoms classiﬁed as treatment-related (loss of
appetite, fatigue) and tumor-related (cough, dyspnea, hemoptysis, pain). In the subgroup of patients with wild-type
EGFR, the TWS was generally longer in the PC/G group (n ¼ 13) than in the G group (n ¼ 8) for the tumor-related
LCSS symptoms. Conclusion: In this study population clinically selected to respond to geﬁtinib, the LCSS scores
were more favorable in the G group than in the PC/G group. Patients with wild-type EGFR tended to show greater1Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Lilly
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improvement in tumor-related LCSS symptoms with chemotherapy than with geﬁtinib alone. These LCSS outcomes
provide further evidence that patients with wild-type EGFR might not beneﬁt from ﬁrst-line treatment of advanced
NSCLC with geﬁtinib.
Clinical Lung Cancer, Vol. 17, No. 2, 150-60 ª 2016 Eli Lilly and Company. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung cancer is the leading incident cancer and cause of cancer
mortality in East Asia, accounting for an estimated 19% of new
cancer cases and 26% of cancer deaths.1 Worldwide, lung cancer
accounts for an estimated 13% and 19% of new cancer cases and
cancer deaths, respectively.1 Advances have been made in the
treatment of nonesmall-cell lung cancer (NSCLC) such that it is no
longer treated as a monolithic disease but as subsets of disease
characterized by genotypic markers such as the epidermal growth
factor receptor (EGFR) gene.2 Selected patients with activating
EGFR mutations have achieved response rates as great as 70% to
treatment with the EGFR tyrosine kinase inhibitor (TKI) geﬁtinib.3
The clinical characteristics associated with a greater incidence of
activating EGFR mutations and an increased likelihood of a
response to geﬁtinib include female gender, East Asian ethnicity,
nonsmoking history, and adenocarcinoma histologic features.4-7
The predictive and prognostic effects of activating EGFR muta-
tions,3 along with country-speciﬁc lung cancer care, insurance, and
general economic conditions, warrant the development of Asian-
speciﬁc NSCLC treatment guidelines.8 In the absence of such
guidelines, practitioners in Asia must rely on the National
Comprehensive Cancer Network guidelines (or national adaptations
of these) or other recognized guidelines (eg, American Society of
Clinical Oncology, American College of Chest Physicians).8 These
guidelines state that the current standard of care for chemotherapy-
naive patients with advanced NSCLC and a good performance
status is platinum-based 2-drug chemotherapy regimens.9-11 In
addition, ﬁrst-line geﬁtinib has been recommended for patients with
activating EGFR mutations.9-11
The present report describes the quality of life (QoL) results of a
previously reported randomized phase III study comparing peme-
trexed plus cisplatin followed by maintenance geﬁtinib (PC/G) with
geﬁtinib monotherapy (G) in chemotherapy-naive patients with
locally advanced or metastatic nonsquamous NSCLC and unknown
EGFR mutation status at study entry.12 The study population was
clinically selected for a favorable response to geﬁtinib treatment, in
that the population was East Asian, never-smokers or light ex-
smokers, and mostly with tumors of adenocarcinoma histologic
type. The efﬁcacy outcomes found no signiﬁcant differences in
progression-free survival (PFS) between the PC/G and G groups in
the intent-to-treat (ITT) population (median PFS, 8.38 and 9.63
months in the PC/G and G groups, respectively), although the
unadjusted hazard ratio (HR) favored PC/G (unadjusted HR
[PC/G vs. G], 0.85; 95% conﬁdence interval [CI], 0.63-1.13;
P ¼ .261).12 A prespeciﬁed subgroup analysis found that the
treatment-by-EGFR mutation status interaction was signiﬁcant forPFS (P ¼ .008).12 In that analysis, PFS was not signiﬁcantly
different between the PC/G and G groups for EGFR
mutation-positive patients (adjusted HR, 0.83; 95% CI, 0.42-1.62;
P ¼ .585). However, the PFS was signiﬁcantly longer in the PC/G
group than in the G group for the patients with wild-type EGFR
(adjusted HR, 0.18; 95% CI, 0.06-0.51; P ¼ .001).12 These results
underline the importance of knowing a patient’s EGFR mutation
status to predict whether the patient will beneﬁt from EGFR TKI
treatment, even in the presence of clinical characteristics associated
with an increased likelihood of response.
The effects of treatment on the palliation of symptoms and
improvement or maintenance of QoL are also important consider-
ations in the choice of lung cancer therapy.13-15 Most patients with
advanced NSCLC will experience symptoms at some point during
their disease course. These can be classiﬁed as disease-speciﬁc (eg,
cough, hemoptysis, pain, dyspnea) or treatment-related (eg, fatigue,
anorexia).16 Evidence for this dual classiﬁcation of LCSS symptoms
has come, at least in part, from the modeling reported by Hatﬁeld
et al.17 Treatment of advanced NSCLC can improve the underlying
disease but, at the same time, worsen the symptom burden owing to
treatment-related toxicity.18 In this previously reported study,12 the
disease-speciﬁc symptoms and QoL were evaluated using the Lung
Cancer Symptom Scale (LCSS).19 The LCSS evaluates 6 major
symptoms associated with lung malignancies and their effect on
overall symptomatic distress, functional activities, and global QoL.
The objective of the present secondary analysis was to examine the
symptoms and QoL of patients with advanced NSCLC in the PC/G
and G groups of the overall population and in the subgroup of
patients with wild-type EGFR. In particular, the effects of the 2
treatment regimens on the LCSS symptoms classiﬁed as treatment-
related and tumor-related symptoms were assessed.
Patients and Methods
Study Design
The full details of the study design have been previously pub-
lished (ClinicalTrials.gov identiﬁer, NCT01017874).12 In brief, the
study was a multicenter, open-label, randomized phase III trial
comparing PC/G and G in East Asian patients with locally advanced
or metastatic nonsquamous NSCLC. The study was conducted at
12 sites in Hong Kong, the Republic of Korea, Singapore, Taiwan,
and Thailand. The eligible patients were never-smokers or light ex-
smokers, whose EGFR mutation status at study entry was unknown
or inconclusive after testing and who had presented with locally
advanced or metastatic (stage IIIB, T4-malignant pleural effusion,
or stage IV) NSCLC, of nonsquamous histologic type. The patients
were randomized 1:1 to receive either pemetrexed plus cisplatinClinical Lung Cancer March 2016 - 151
Quality of Life in Patients With Advanced NSCLC
152 -(500 mg/m2 pemetrexed followed by 75 mg/m2 cisplatin on day 1
of a 21-day cycle for a maximum of 6 cycles) followed (in patients
without progression) by geﬁtinib maintenance therapy (250 mg/d)
(PC/G group) or geﬁtinib monotherapy (250 mg/d) (G group).
Treatment was continued until disease progression, discontinuation,
or death. The ethics review board at each site approved the study
protocol, and the study was conducted in accordance with the Good
Clinical Practice guidelines and the Declaration of Helsinki. All
patients provided written informed consent before undergoing any
study procedure, with separate consent obtained for optional pro-
vision of tissue samples for biomarker analysis. The study was
registered at the ClinicalTrials.gov website (ClinicalTrials.gov
identiﬁer, NCT01017874).
QoL Assessments
QoL was assessed using the LCSS,19 with a 24-hour recall period.
The measurements were collected at baseline, at each study visit,
and once after discontinuation of treatment. The LCSS data
included patient ratings of 6 symptoms (loss of appetite, fatigue,
cough, dyspnea, hemoptysis, and pain) and 3 summary items
(overall symptoms, interference with daily activities, and overall
QoL). Each of the 9 LCSS items was scored using a 100-mm visual
analog scale, with lower values representing lower symptom severity,
lower symptom burden, less interference with normal activities, or
better QoL than higher values.
EGFR Mutation Status
Where possible, patient tissue samples were retrospectively
analyzed for EGFR mutations, as described previously.12 The pa-
tients were classiﬁed as wild-type EGFR (EGFR-WT), EGFR
mutation-positive, or EGFR mutation status unknown.
Outcomes
The patient-reported outcomes, measured using the LCSS
questionnaire, were compared between the PC/G and G groups as a
secondary objective of the study. In addition, a post hoc analysis of
the QoL outcomes in patients with wild-type EGFR in the PC/G
and G groups was conducted.
Statistical Analysis
The LCSS analyses were conducted on the ITT QoL population
and the EGFR-WT QoL subgroup. The ITT QoL population was
deﬁned as the population of patients with a completed LCSS
assessment ( 1 question from the LCSS) at baseline and at least
once during the study. The EGFR-WT QoL subgroup was deﬁned
as the population of patients with wild-type EGFR and a completed
LCSS assessment at baseline and at least once during the study. The
time to worsening of symptoms (TWS) was measured from the date
of randomization to the ﬁrst date of a clinically meaningful wors-
ening for each of the LCSS items. Worsening of symptoms was
deﬁned as a one-half standard deviation change, determined from
the corresponding baseline item scores.20 The TWS was censored at
the date of the patient’s last LCSS assessment for patients whose
LCSS status was unknown or who had been lost to follow-up. The
TWS was analyzed using the Kaplan-Meier estimator. The HRs
were estimated using unadjusted Cox regression analysis with
assigned treatment as the only covariate. The mean maximumClinical Lung Cancer March 2016improvement compared with the baseline score was calculated for
each of the LCSS items. Correlations of TWS with PFS were
analyzed using Pearson’s correlation coefﬁcient and Kendall’s tau P
value, adjusted for censored observations.21 Correlation coefﬁcients
of 0.2 to < 0.5,  0.5 to < 0.8, and  0.8 represented a low,
moderate, and high correlation, respectively. A negative correlation
coefﬁcient indicated that as 1 variable increased, the other
decreased, and vice versa. Analyses were performed using Statistical
Analysis Systems, version 9.2 (SAS Institute, Cary, NC).
Results
Patient Disposition
A total of 236 patients were enrolled in the ITT population, 118
patients in the PC/G group and 118 patients in the G group. Of
these, LCSS data were available for 109 patients in each group (ITT
QoL population, 218 patients). Of the 236 patients in the ITT
population, 148 (62.7%) consented to the biomarker analyses, 141
(59.7%) provided tissue samples for EGFR mutation analysis, and
EGFR mutation status could be determined for 74 tissue samples.
Overall, 24 patients were classiﬁed as having wild-type EGFR. Of
these 24 patients, 21 had LCSS data available (EGFR-WT QoL
subgroup), 13 in the PC/G group and 8 in the G group.
Demographic and Baseline Clinical Characteristics
In the ITT QoL population, the demographic and baseline
clinical characteristics were similar between the PC/G (n ¼ 109)
and G (n ¼ 109) groups (Table 1). The median baseline LCSS
scores were relatively low, indicating a low symptom burden, in
both the PC/G and the G groups. The highest median scores were
for overall QoL in the PC/G group (26.0 mm) and for fatigue and
overall QoL in the G group (31.0 mm for both). Slight differences
were seen between the 2 groups in the median baseline LCSS scores
for some symptoms.
In the EGFR-WT QoL subgroup, the demographic and baseline
clinical characteristics were similar between the PC/G (n ¼ 13) and
G (n ¼ 8) groups, except for the Eastern Cooperative Oncology
Group performance status (Table 1). In the PC/G group, 6 of 13
patients (46.2%) had a performance status of 0, and in the G group,
2 of 8 patients (25.0%) had a performance status of 0. The highest
median LCSS scores at baseline were for overall QoL in the PC/G
group (32.0 mm) and for interference with daily activities in the G
group (52.0 mm). Large differences were seen between the 2 groups
in the median baseline LCSS scores for some symptoms.
Change From Baseline in QoL
In the ITT QoL population, more improvements were seen in the
LCSS scores from baseline in the G group than in the PC/G group
(Figure 1). In the PC/G group, median decreases from baseline
occurred in the cough scores, indicating improvement, after each of
the 6 cycles of chemotherapy (Figure 1). No change or a worsening in
LCSS scores was seen for all other symptoms, including overall
symptoms, interference with activity levels, and overall QoL. In the G
group, an improvement or no change was seen in the LCSS scores for
all symptoms, including overall symptoms, interference with activity
levels, and overall QoL during treatment (Figure 1).
In the EGFR-WT QoL subgroup, the LCSS scores were more
variable between visits during the study period encompassing the 6
Table 1 Patient Demographics and Baseline Disease Characteristics
Characteristic
ITT QoL Population EGFR-WT QoL Subgroup
PC/G (n [ 109) G (n [ 109) PC/G (n [ 13) G (n [ 8)
Gender, n (%)
Male 29 (26.6) 27 (24.8) 3 (23.1) 2 (25.0)
Age (years)
Mean 58.2 59.7 51.5 54.6
Range 23.7-80.7 30.5-79.2 23.7-67.4 35.7-70.2
Age group
<65 years 74 (67.9) 73 (67.0) 10 (76.9) 6 (75.0)
65 years 35 (32.1) 36 (33.0) 3 (23.1) 2 (25.0)
Smoking status, n (%)
Never-smoker 100 (91.7) 101 (92.7) 12 (92.3) 8 (100.0)
Light ex-smoker 9 (8.3) 8 (7.3) 1 (7.7) 0
Pathologic diagnosis, n (%)
Adenocarcinoma 106 (97.2) 107 (98.2) 12 (92.3) 8 (100.0)
Nonadenocarcinoma 3 (2.8) 2 (1.8) 1 (7.7) 0
Stage of disease, n (%)
IIIB 4 (3.7) 7 (6.4) 0 0
IV 105 (96.3) 102 (93.6) 13 (100.0) 8 (100.0)
ECOG performance status, n (%)
0 47 (43.1) 46 (42.2) 6 (46.2) 2 (25.0)
1 62 (56.9) 63 (57.8) 7 (53.8) 6 (75.0)
Country of enrollment, n (%)
Hong Kong 3 (2.8) 7 (6.4) 1 (7.7) 0
Korea 50 (45.9) 53 (48.6) 3 (23.1) 3 (37.5)
Singapore 1 (0.9) 1 (0.9) 1 (7.7) 0
Taiwan 37 (33.9) 28 (25.7) 3 (23.1) 3 (37.5)
Thailand 18 (16.5) 20 (18.3) 5 (38.5) 2 (25.0)
LCSS symptomsa
Loss of appetite 18.0 (0, 93) 28.0 (0, 94) 12.0 (0, 86) 35.0 (0, 98)
Fatigue 20.0 (0, 98) 31.0 (0, 100) 22.0 (0, 58) 39.0 (0, 62)
Cough 19.0 (0, 100) 20.0 (0, 96) 26.0 (1, 65) 4.0 (0, 77)
Dyspnea 15.0 (0, 100) 11.0 (0, 96) 29.0 (0, 100) 17.0 (0, 82)
Hemoptysis 0 (0, 97) 0 (0, 54) 0 (0, 27) 0 (0, 13)
Pain 6.0 (0, 90) 12.0 (0, 100) 2.0 (0, 69) 3.0 (0, 85)
Overall symptoms 16.0 (0, 100) 17.0 (0, 100) 10.0 (0, 63) 34.0 (0, 83)
Interference with daily
activities
11.0 (0, 98) 15.0 (0, 100) 9.0 (0, 74) 52.0 (0, 90)
Overall QoL 26.0 (0, 98) 31.0 (0, 100) 32.0 (1, 70) 33.0 (0, 90)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; EGFR ¼ epidermal growth factor receptor; G ¼ geﬁtinib monotherapy; ITT ¼ intent-to-treat; LCSS ¼ Lung Cancer Symptom Scale;
PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib; QoL ¼ quality of life; WT ¼ wild-type.
aLCSS results presented as median (minimum, maximum) in millimeters.
Mark Boye et alcycles of chemotherapy than in the ITT QoL population (Figure 1).
This variability in scores was likely related to the small sample size of
the EGFR-WT QoL subgroup (Table 2). In the PC/G group,
median decreases occurred from baseline in the cough LCSS scores
after each of the 6 cycles of chemotherapy (Figure 1). No change or
a worsening was seen in the LCSS scores for loss of appetite,
fatigue, hemoptysis, and interference with activity levels. The LCSS
scores varied between visits for dyspnea, pain, overall symptoms,and overall QoL. For the G group, median decreases from baseline
were seen in the cough, dyspnea, and interference with activity
levels scores (Figure 1). The LCSS scores varied between visits for all
other symptoms, including overall symptoms and overall QoL.
Time to Worsening of QoL Symptoms
In the ITT QoL population, the TWS was generally longer in the
G group than in the PC/G group for the treatment-related (loss ofClinical Lung Cancer March 2016 - 153
Figure 1 Change From Baseline in Lung Cancer Symptom Scale (LCSS) Symptoms in the Intent-to-treat (ITT) Quality of Life (QoL)
Population and Epidermal Growth Factor Receptor Wild-Type (EGFR-WT) QoL Subgroup. Median Change From Baseline in
LCSS Symptom Score at Each Visit for Each of the 4 Groups. Lower Values Represent Lower Symptom Severity, Lower
Symptom Burden, Less Interference With Normal Activities, or Better QoL Than Higher Values. Note that in the G Group of the
EGFR-WT QoL Subgroup, Only 2 Patients Had QoL Data Available at Visits 3 and 4 and Only 1 Patient Had QoL Data Available
at Visits 5 and 6
Abbreviations: G ¼ geﬁtinib monotherapy; PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib.
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154 -appetite, fatigue) and tumor-related (cough, dyspnea, hemoptysis,
pain) LCSS symptoms (Figure 2). In addition, the TWS was longer
in the G group than in the PC/G group for the summary items of
overall symptoms and interference with daily activities. The median
TWS was numerically longer in the G group than in the PC/G
group for all LCSS items, except for hemoptysis (Figure 3A). The
median TWS ranged from 2.99 months for loss of appetite to 19.45Clinical Lung Cancer March 2016months for hemoptysis in the PC/G group and from 6.93 months
for overall QoL to 18.23 months for dyspnea in the G group.
In contrast to the ITT QoL population, in the EGFR-WT QoL
subgroup, the TWS was generally longer in the PC/G group than in
the G group for the tumor-related LCSS symptoms (Figure 2).
However, it was difﬁcult to interpret the Kaplan-Meier curves for
several items because of the small sample size in the EGFR-WT
Table 2 Sample Size at Visits 1 to 6
Group
Visit
1 2 3 4 5 6
ITT QoL population (n)
PC/G 109 99 91 85 80 77
G 108 98 79 75 69 65
EGFR-WT QoL
subgroup (n)
PC/G 13 12 12 11 9 9
G 8 6 2 2 1 1
Abbreviations: EGFR ¼ epidermal growth factor receptor; G ¼ geﬁtinib monotherapy; ITT ¼ intent-to-treat; PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib; QoL ¼ quality of life;
WT ¼ wild-type.
Mark Boye et alQoL subgroup. Similarly, the median TWS could not be estimated
for several LCSS items because of the small sample size (Figure 3B).
The median TWS in the EGFR-WT QoL subgroup ranged from
3.25 months for loss of appetite to 8.94 months for dyspnea in the
PC/G group and from 3.48 months for fatigue to 4.07 months for 5
items (loss of appetite, dyspnea, hemoptysis, overall symptoms, and
overall QoL) in the G group.
Maximum Improvement in QoL Symptoms
In the ITT QoL population, clinically detectable mean
maximum improvements were observed for all LCSS items, except
for hemoptysis (both groups) and pain (PC/G group). The mean
maximum improvements were greater in the G group than in the
PC/G group for loss of appetite, fatigue, and pain (Figure 4A). The
mean maximum improvements were lower in the G than in the PC/
G group for cough and were similar between the 2 groups for
dyspnea and hemoptysis. The mean maximum improvements in the
3 LCSS summary items were slightly greater in the G group than in
the PC/G group. In the EGFR-WT QoL subgroup, clinically
detectable mean maximum improvements were observed for 7 of 9
and 4 of 9 LCSS items in the PC/G and G groups, respectively. The
mean maximum improvements were greater in the PC/G group
than in the G group for all LCSS symptoms, except for fatigue and
the summary item of interference with daily activities (Figure 4B).
Correlation of TWS and PFS
In the ITT QoL population, low correlations were found between
PFS and TWS for 7 of the 9 LCSS items (range, 0.33-0.49) and
moderate correlations for 2 of the 9 LCSS items (range, 0.52-0.53;
Figure 5). In the EGFR-WTQoL subgroup, the estimated correlation
was close to 0 or negative for loss of appetite, overall symptoms,
interference with daily activities, and overall QoL (Figure 5). This
might suggest a different correlation pattern betweenPFS andTWS in
the EGFR-WT QoL group than in the ITT QoL population.
However, the correlation estimates were very sensitive to individual
observations because of the very small sample size.
Discussion
In the present randomized phase III study of East Asian patients
with advancedNSCLC and unknown EGFRmutation status at study
entry who were clinically selected for a favorable response to geﬁtinib
treatment, the LCSS outcomes improved in patients in the G groupbut mostly remained the same or worsened in patients in the PC/G
group. Improvements were seen in a greater number of LCSS scores,
the time to worsening of LCSS scores was longer, and the mean
maximum improvements in the LCSS scores were greater in the G
group than in the PC/G group. However, the symptom burden in the
overall study population was mild at baseline, which would favor the
less toxic treatment (ie, geﬁtinib monotherapy), and approximately
68% of patients for whom the EGFR mutation status could be
determined were EGFR mutation-positive, suggesting that most pa-
tients would be likely to respond to, and have an improvement in
LCSS outcomes from, geﬁtinib treatment. The proportion of patients
determined to be EGFR mutation-positive in the present study was
consistent with the ﬁnding from a prospective multicountry epide-
miology study conducted in Asia with an overall EGFR mutation
frequency of 51.4% (61.1% in women and 44.0% in men).22
In contrast to the overall study population, the post hoc analysis
of LCSS outcomes in the small subgroup of patients with wild-type
EGFR appeared to show improvements in some of the tumor-
related LCSS symptoms in patients receiving PC/G compared
with those receiving G. In conjunction with the previously reported
efﬁcacy outcomes of the study,12 these results suggest that patients
with wild-type EGFR do not respond to geﬁtinib treatment. Thus,
their LCSS outcomes might be worse during treatment than those
receiving chemotherapy. In addition, this suggests that QoL might
be more closely related to the efﬁcacy of the treatment regimen than
to its toxicity. However, the small sample size of the EFGR-WT
QoL subgroup precluded any deﬁnitive conclusions from this
post hoc analysis. Nevertheless, the QoL results for chemotherapy
versus geﬁtinib in patients with wild-type EGFR in the present
study are consistent with those reported for a subset of patients with
advanced NSCLC with wild-type EGFR in the TORCH (Tarceva
or Chemotherapy) study.23 In that study, ﬁrst-line treatment with
the EGFR TKI erlotinib (n ¼ 83) was associated with worse out-
comes compared with ﬁrst-line cisplatin-gemcitabine (n ¼ 82) for
each of the selected European Organissation for Research and
Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-
LC13 QoL items reﬂecting disease-related effects (global QoL,
physical functioning, cough, dyspnea, and pain) in patients with
wild-type EGFR.23
The improvements in QoL observed in patients receiving geﬁ-
tinib monotherapy compared with those receiving chemotherapy in
the overall study population were consistent with the ﬁndings fromClinical Lung Cancer March 2016 - 155
Figure 2 Probability of Time to Worsening of Symptoms. Probabilities Reported as Hazard Ratios (HRs) With 95% Conﬁdence
Intervals. Because of the Small Sample Size, P Values Could Not Presented for the Epidermal Growth Factor Receptor Wild-
Type (EGFR-WT) Quality of Life (QoL) Subgroup
Abbreviations: G ¼ geﬁtinib monotherapy; ITT ¼ intent-to-treat; PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib.
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156 -2 other studies of geﬁtinib in chemotherapy-naive patients clinically
selected to be likely to respond to geﬁtinib (ie, East Asian never-
smokers or light ex-smokers with adenocarcinoma). In the Iressa
Pan-Asia Study (IPASS), improvements in QoL were signiﬁcantly
greater in the geﬁtinib group (n ¼ 590) than the carboplatin-
paclitaxel group (n ¼ 561), as assessed using the Functional
Assessment of Cancer Therapy-Lung (FACT-L) total score and the
Trial Outcome Index.24 Symptom improvement rates, assessed
using the FACT-L Lung Cancer Subscale (LCS), were similar in the
2 groups. In the First-SIGNAL study, improvements in QoL were
signiﬁcantly greater in the geﬁtinib group (n ¼ 156) than the
gemcitabine-cisplatin group (n ¼ 148), as assessed by the EORTC
QLQ-C30 questionnaire, with respect to physical, role, and social
function.25 The results of these studies indicate that geﬁtinib
treatment is associated with better QoL than chemotherapy inClinical Lung Cancer March 2016patients with NSCLC clinically selected to respond to geﬁtinib.
Because the patients responding to geﬁtinib treatment are EGFR
mutation-positive, the EGFR mutation status should be determined
before treatment, and only those patients who are EGFR mutation-
positive should be treated with geﬁtinib.
The results of the post hoc analysis of LCSS outcomes in the
subgroup of patients with wild-type EGFR in the present study
suggest that the time to worsening of the LCSS symptoms that
can be classiﬁed as tumor-related (ie, cough, dyspnea, hemopty-
sis, and pain) rather than treatment-related (ie, anorexia and fa-
tigue) was longer in patients receiving chemotherapy than in
those receiving geﬁtinib. Given the small numbers of patients in
the PC/G and G groups in the EGFR-WT QoL subgroup, the
imbalance in the number of patients between these 2 groups after
visit 2 and the variation in the distribution of patients having a
Figure 3 Median Time to Worsening of Symptoms (TWS) in the
(A) Intent-to-treat (ITT) Quality of Life (QoL)
Population and (B) Epidermal Growth Factor Receptor
Wild-Type (EGFR-WT) QoL Subgroup. The Median
Could Not Be Estimated Because of the Small Sample
Size
Abbreviations: EGFR ¼ epidermal growth factor receptor; G ¼ geﬁtinib monotherapy;
ITT ¼ intent-to-treat; PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib;
QoL ¼ quality of life; WT ¼ wild-type.
Figure 4 Mean Maximum Improvement in Lung Cancer
Symptom Scale (LCSS) Items in the (A) Intent-to-treat
(ITT) Quality of Life (QoL) Population and (B)
Epidermal Growth Factor Receptor Wild-Type (EGFR-
WT) QoL Subgroup. Clinically Detectable Improvement
(Dotted Line) Deﬁned as a 10-Point Reduction in LCSS
Scores
Abbreviations: EGFR ¼ epidermal growth factor receptor; G ¼ geﬁtinib monotherapy;
ITT ¼ intent-to-treat; PC/G ¼ pemetrexed plus cisplatin followed by maintenance geﬁtinib;
QoL ¼ quality of life; WT ¼ wild-type.
Mark Boye et alperformance status of 0 versus 1 in these 2 groups, these results
should be interpreted with caution. However, these results are in
line with the post hoc analysis results of patient-reportedoutcomes in the subgroup of patients with wild-type EGFR in the
IPASS, which found that improvements in symptoms and QoL,
assessed using the FACT-L, Trial Outcome Index, and FACT-LClinical Lung Cancer March 2016 - 157
Figure 5 Correlation of Time to Worsening of Symptoms With Progression-Free Survival. P Value Is Kendall’s Tau P Value Adjusted for
Censored Observations. Probabilities Are Reported as Pearson’s Correlation Coefﬁcient (PCC; 95% Conﬁdence Interval). The
Epidermal Growth Factor Receptor Wild-Type (EGFR-WT) Quality of Life (QoL) Subgroup Was a Subgroup of the Intent-to-
treat (ITT) QoL Population. All Data Points (Red and Black) Denote the ITT QoL Population. Red Data Points Denote the EGFR-
WT QoL Subgroup Only. The Line of Correlation for the ITT QoL Population Was Calculated From All Noncensored Data Points
(ie, Red and Black). The Line of Correlation for the EGFR-WT QoL Subgroup Was Calculated From the Red Data Points Only.
For the Cough Scatter Plot, 1 Data Point Was Outside the Range of the Graph (Not Shown) But Was Used in the Calculation of
the Line of Correlation. Correlation Coefﬁcients of 0.2 to < 0.5, ‡ 0.5 to < 0.8, and ‡ 0.8 Represented Low, Moderate, and
High Correlation, Respectively
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158 -LCS were signiﬁcantly greater in the carboplatin-paclitaxel group
(n ¼ 80) than in the geﬁtinib group (n ¼ 89).24 Taken together
with the longer PFS reported for patients with wild-type EGFR
who received chemotherapy versus geﬁtinib in both the current
study12 and the IPASS,26 these results provide further evidence
that patients with wild-type EGFR might not beneﬁt from
treatment with geﬁtinib. Therefore, although ethnic origin,Clinical Lung Cancer March 2016smoking status, and histologic ﬁndings aid in the identiﬁcation of
patients with NSCLC likely to have an EGFR mutation,6,7 the
accumulating evidence suggests that, whenever possible, the
EGFR mutation status should be determined to make the most
appropriate choice of treatment for advanced NSCLC.26
The 6 symptoms associated with lung cancer assessed by the LCSS
can be classiﬁed as treatment-related (loss of appetite and fatigue) and
Mark Boye et altumor-related (cough, dyspnea, hemoptysis, and pain). In the ITT
QoL population in the present study, patients receiving geﬁtinib
monotherapy experienced improvements in both treatment-related
and tumor-related LCSS symptoms; however, in the EGFR-WT
QoL subgroup, the improvements in symptoms in patients
receiving chemotherapy were mostly conﬁned to the tumor-related
LCSS symptoms. This observation was likely to be related to the
different adverse event proﬁles associated with the 2 treatment regi-
mens, with loss of appetite and fatigue more likely to occur with
pemetrexed-cisplatin treatment than with geﬁtinib treatment.27-30
In the present study, correlations seemed to be present between
TWS and PFS in the overall study population. This suggests that a
delay in the worsening of symptoms, as assessed by the LCSS, might
be associated with delayed tumor progression. However, because of
the small number of patients, the correlation data for the patients
with wild-type EGFR were less interpretable. Correlations between
QoL outcomes and efﬁcacy outcomes have been reported in other
studies of advanced NSCLC.31-33 In addition, in a post hoc analysis
of geﬁtinib-treated patients in the IPASS, a greater percentage of
patients with tumor progression experienced deterioration in QoL
and symptoms at 4 months compared with patients without tumor
progression.34 These correlation analyses suggest that, in addition to
providing information on the palliation of symptoms, QoL analyses
can provide complementary efﬁcacy data.32
EGFR mutation status was not known at study entry, reﬂecting
clinical practice in which the EGFR mutation status is not always
known, the EGFR mutation results are inconclusive, or a tumor
sample is not available.12 Although the present study had the
advantage of the retrospective determination of the EGFR mutation
status, this was determined for only a low proportion of patients:
141 of 236 patients (59.7%) provided tissue samples for EGFR
mutation analysis, and EGFR mutation status could not be deter-
mined for 67 of the 141 patients (47.5%) who provided tissue
samples. Overall, the EGFR mutation status was determined for
only 74 of the 236 patients (31.4%) randomized in the present
study. Another limitation of our study was that it was not powered
to determine statistically signiﬁcant differences between the 2
treatment groups for QoL in either the ITT QoL population or the
EGFR-WT QoL subgroup for the conducted analyses. For the
EGFR-WT QoL subgroup speciﬁcally, an imbalance was present
between the PC/G and G groups in the performance status at
baseline and in the number of patients with QoL data available after
visit 2.
Conclusion
In the present study population of patients with advanced
NSCLC who had been clinically selected to respond to geﬁtinib, the
LCSS outcomes appeared to be improved with geﬁtinib compared
with chemotherapy. In contrast, the efﬁcacy outcomes from the
study found no signiﬁcant differences between the 2 treatment
regimens with respect to PFS.12 In the subgroup of patients with
wild-type EGFR, indications were found that tumor-related LCSS
symptoms might be improved with chemotherapy compared with
geﬁtinib, consistent with the observation of greater clinical efﬁcacy
for PC/G in this patient population.12 In conjunction with the
efﬁcacy outcomes from this study, these patient-reported LCSS
outcomes provide supporting evidence that patients with wild-typeEGFR might not beneﬁt from treatment of advanced NSCLC with
EGFR TKIs in the ﬁrst-line setting.
Clinical Practice Points
 Previously reported efﬁcacy results from this randomized phase
III study found no signiﬁcant difference in PFS between PC/G
compared with G in East Asian never-smoker patients with
advanced NSCLC and unknown EGFR mutation status.12
 In this study population, clinically selected to respond to geﬁ-
tinib, the QoL analysis revealed that the LCSS scores were more
favorable in the G group than in the PC/G group.
 In particular, the TWS was generally longer in the G group than
in the PC/G group for the LCSS symptoms classiﬁed as
treatment-related (loss of appetite, fatigue) and those classiﬁed as
tumor-related (cough, dyspnea, hemoptysis, pain).
 In the subgroup of patients with wild-type EGFR, the TWS was
generally longer in the PC/G group than in the G group for the
tumor-related LCSS symptoms.
 Combined with the previously published efﬁcacy results for this
subgroup,12 these QoL results provide further evidence that
patients with wild-type EGFR will not beneﬁt from treatment
with an EGFR TKI.
 The combined results from the present study further demon-
strate the importance of determining EGFR mutation status,
rather than relying solely on the clinical characteristics, to guide
the selection of ﬁrst-line treatment for patients with advanced
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